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Genetic instability has emerged as an important hallmark of human neoplasia. Although most types of cancers exhibit
genetic instability to some extent, in colorectal cancers genetic instability is a distinctive characteristic. Recent studies
have shown that deregulation of genes involved in sister chromatid cohesion can result in chromosomal instability in
colorectal cancers. Here, we show that the replisome factor minichromosome maintenance complex–binding protein
(MCMBP), which is directly involved in the dynamics of theminichromosomemaintenance complex and contributes to
maintaining sister chromatid cohesion, is transcriptionallymisregulated in different typesof carcinomas.Cellular studies
revealed that bothMCMBP knockdownandoverexpression in different breast and colorectal cell lines is associatedwith
the emergence of a subpopulation of cells with abnormal nuclear morphology that likely arise as a consequence of
aberrant cohesion events. Association analysis integrating gene expression data with clinical information revealed that
enhanced MCMBP transcript levels correlate with an increased probability of relapse risk in colorectal cancers and
different types of carcinomas. Moreover, a detailed study of a cohort of colorectal tumors showed that the MCMBP
protein accumulates to high levels in cancer cells, whereas in normal proliferating tissue its abundance is low, indicating
that MCMBP could be exploited as a novel diagnostic marker for this type of carcinoma.
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http://dx.doi.org/10.1016/j.neo.2014.07.011For a cell to generate two daughter cells, faithful DNA rep-
lication and partitioning of the sister chromatids to each of the
newly formed cells is of utmost importance, preventing the
transmission of potentially harmful mutations to the daughter
cells, which otherwise might result in developmental defects or
cancer. The set of molecular events that lead to the generation of
genetic abnormalities is known as genetic instability. Genetic
instability can be broadly divided into two major groups. The
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chromosomal alterations that might lead to acquisition or loss of
entire chromosomes, as well as duplication, translocation, inversion,
or deletion of particular chromosomal segments. The second is
instability at the nucleotide level due to defective DNA replication
and faulty DNA repair pathways [1]. Defects in either replication or
checkpoint responses increase the susceptibility to cancer by
triggering genome instability [2].
Genetic instability has emerged as a new hallmark of human
cancers [3]. The development of new technologies such as
comparative genomic hybridization has extensively demonstrated
gain and loss of gene copy numbers in malignantly transformed cells
in many different types of carcinomas [4]. Different tumors can
harbor drastically different genome alterations. These include a large
number of defects in the cellular machinery that regulates DNA
replication and DNA repair. Together, these observations suggest that
genome instability is rather widespread in cancer cells. Although some
degree of genetic instability is seen in different types of cancers, it is a
distinctive characteristic of colorectal cancers [5,6]. Strikingly, only a
few genes that might cause genetic instability have been identified and
no general mechanism that can explain the origin of this phenotype
has emerged.
The most distinctive characteristic of some types of cancers,
including colorectal carcinomas, is CIN due to loss of sister chromatid
cohesion [7,8]. This clearly illustrates that defects in sister chromatid
cohesion can progress to tumorigenesis and cancer.
A new member of the minichromosome maintenance (MCM)
complex was identified in humans and denoted as MCM-binding
protein (MCMBP) [9]. The MCM complex is considered the main
replicative helicase of the cell and it is highly conserved throughout
eukaryotes. The MCM protein family is characterized by the AAA
ATPase motif. The replicative helicase consists of six related core
subunits (MCM 2-7) that form a hexameric ring. Metazoans and
plants have additional MCM subunits, as well as developmentally
specific versions of the complex. In the late M and early G1 cell cycle
phases, the MCM complex is recruited onto chromatin as part of the
prereplication complex, where it functions as the molecular engine
that unwinds the duplex DNA and also powers fork progression
during DNA replication [10].
It was proposed that MCMBP can replace MCM2, which would
lead to the formation of a different complex with MCM 3 to 7 [9].
Additionally, recent studies have postulated that MCMBP can
disassemble the MCM2–7 complex and might function as an
unloader of the MCM complex from chromatin, redistributing the
MCM proteins at the end of the S phase [11,12]. Complementing
previous observations, our experiments demonstrated that depletion
of the plant MCMBP orthologue, the ETG1 protein, resulted in late
G2 cell cycle arrest, correlating with a partial loss of sister chromatid
cohesion. Similarly, cohesion defects were observed upon knockdown
of the MCMBP gene in human cell cultures, suggesting that this
evolutionarily conserved protein has an equally important role in
mammals [13,14].
Here, we show that deregulation of MCMBP in different breast
and colorectal cancer cell lines is associated with the emergence of a
subpopulation of cells with abnormal nuclear morphology that
emerges as a consequence of aberrant cohesion events. Association
analysis integrating gene expression data with clinical information
revealed that alteration ofMCMBP transcript levels correlates with an
increment in the probability of relapse risk in different types ofhuman carcinomas. Finally, a detailed study of different colorectal
tumor cohorts showed that the MCMBP protein is highly abundant
in colorectal adenocarcinomas. These data suggest that deregulation
of MCMBP can drive the oncogenic transformation of different
cancer types.Materials and Methods
Gene Ontology Analysis
To identify significantly overrepresented Gene Ontology (GO)
categories among the MCMBP coexpression neighborhood, the 300
genes most coexpressed with MCMBP were retrieved from COX-
PRESdb [15].We then, used the BiNGOplugin fromCytoscape [16] to
determine the enrichedGOcategories, using aP valueb .01 according to
a multiple t test with correction for false positives.
MCMBP Antibody Generation
To produce recombinant MCMBP protein, the cDNA sequence
encoding the human MCMBP was polymerase chain reaction (PCR)
amplified and cloned between the BamHI and NotI sites into the
pGEX-6P-2 vector by using the In-Fusion PCR cloning system. pGEX-
6P-2–hMCMBP plasmid was transformed in Escherichia coli strain
MC1061 containing the transcription regulatory plasmid pICA2,
which allows tight Isopropyl-beta-D-thiogalactoside (IPTG)-inducible
expression regulation [17]. Exponentially growing cultures (28°C) were
induced with 1.0 mM isopropyl-β-D-thiogalactopyranoside and
incubated overnight at 20°C. Cell pellets were resuspended in buffer
A [phosphate-buffered saline (PBS, pH 7.4), DNase I (1 mg/100 ml;
Roche Diagnostics, Indianapolis, IN), and complete EDTA-free
Protease Inhibitor Cocktail Tablets (Roche Diagnostics)] and lysed by
sonication. Insoluble proteins were removed by centrifugation. The
supernatant was applied to a glutathione sepharose 4FF column (GE
Healthcare, Little Chalfont, Buckinghamshire, UK) pre-equilibrated
with buffer B (PBS, pH 7.4). Glutathione S-transferase (GST)–
tagged hMCMBP was eluted from the column with buffer C [50
mM Tris-HCl (pH 8.0), 100 mM NaCl, and 10 mM reduced
glutathione]. Elution fractions containing GST-hMCMBP were
pooled and dialyzed against buffer D [50 mM Tris-HCl (pH 7.0),
150 mM NaCl, 1 mM EDTA, and 1 mM DTT]. The GST-
hMCMBP fusion protein was digested with the PreScission Protease
(GE Healthcare) to clip off GST. The digested sample was run on a
glutathione sepharose 4B column (GE Healthcare) pre-equilibrated
with buffer B for removal of the GST tag and the PreScission
Protease. Flow-through fractions containing hMCMBP were
pooled. The purified recombinant hMCMBP protein was dialyzed
to buffer B. The purity of the fractions was checked by means of
sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Endo-
toxin removal was obtained by applying the purified hMCMBP
sample to an ActiClean Etox column (Sterogene, Carlsbad, CA) pre-
equilibrated with buffer B.
Anti-human MCMBP antisera were obtained by immunizing rabbits
with full-length MCMBP protein. Two different rabbits were
immunized with 0.5 μg of antigen in a volume of 0.5 ml. The
immunizations were carried out subcutaneously 14, 28, and 56 days
after the first preimmune bleeding. Blood was collected on days 38, 66,
and 80. Recombinant hMCMBP was immobilized to NHS-activated
sepharose (GE Healthcare). Rabbit anti-hMCMBP serum was run on
the affinity resin pre-equilibrated with buffer B (PBS, pH 7.4). Bound
rabbit IgGs were eluted from the column with buffer E [100 mM
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M Tris. Elution fractions containing the rabbit IgG were pooled. The
purity of the fractions was checked by means of sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.
Generation of Stable MCF7 and MDA-MB-231 Lines
with Constitutive Knockdown of MCMBP or with
MCMBP Overexpression
The lentiviral construct V2HS-158067 (Catalog No. RHS4430-
99167940) to knock down MCMBP (C10ORF119) was purchased
from Open Biosystems (Lafayette, CO). Similarly, for the overex-
pression of MCMBP, a lentiviral construct containing the complete
ORF of the MCMBP gene (C10ORF110) was obtained from Open
Biosystems (MHS1011-58896) and cloned in the pDWPITe-
toMCMBPv5His vector. Following the manufacturer's instructions,
the Qiagen midi-preps extraction kit was used to obtain 100 μl of
V2HS-158067 construct at 1 μg/μl, for transfecting human
embryonic kidney–293 (HEK-293) cells to produce viral particles.
Three different constructs were used to produce the final DNAmix for
transfecting HEK-293 cells. Three microliters of pCMVD8-9-MCO23,
1.5 μl of pMG-MCO22, and 3 μl of V2HS-158067 (each at a
concentration of 1 μg/μl) were mixed with 1 μl of 1 M sodium acetate,
3 μl of absolute ethanol, and 8.5 μl of bi-distillated water to obtain a
final volume of 20 μl. The material was gently mixed by pipetting
and placed at −70°C for 30 minutes, after which it was centrifuged at
maximum speed for 30 minutes at 4°C. The supernatant was
removed and the pellet was washed with 250 μl of 70% ethanol. The
mixture was again centrifuged at maximum speed for 5 minutes at
4°C, and the supernatant was discarded. The pellet was dried at room
temperature and resuspended in 10 μl of bi-distillated water. HEK
cells were grown in 25-cm2 flasks in 5 ml of complete medium
(Dulbecco's modified Eagle's medium with 10% fetal calf serum) at
37°C in 5% CO2. Two days before transfection, HEK cells were
trypsinized, split into six-well plates containing 4 ml of fresh culture
medium, and incubated at 37°C in 5%CO2 for 2 days. At the time of
transfection, the cells were still subconfluent.
A calcium phosphate precipitate suspension was prepared in two 5-
ml tubes. In one of these tubes, 250 μl of Hepes-buffered saline
solution was dispensed (16.4 g of NaCl, 11.9 g of Hepes acid, and
0.21 g of Na2HPO4 per liter, pH 7.05). In the other tube, a solution
containing 10 μl of the lentiviral mix, 190 μl of TE buffer, and 50 μl
of 2.5 M CaCl2 was prepared; it was then added dropwise to the tube
containing the Hepes buffer. Afterward, the solution was vortexed
gently for 30 seconds and then left for 10 minutes at 37°C to allow
the calcium phosphate to precipitate. Then, 4 μl of 25 mM
chloroquine was added to the mix. Subconfluent HEK cells were
transfected by adding 250 μl of the DNA mix to the cultured cells.
HEK cells were grown for 8 hours at 37°C in 5% CO2, and the
culture medium was refreshed. Finally, the HEK cells were grown for
2 days to produce viral particles. They were then trypsinized, collected
in 15-ml tubes, and filtered through a syringe and a 0.45-μm filter.
The filtered suspension of viral particles was divided into aliquots of 1
ml in 1.5-ml centrifuge tubes and stored at −80°C.
MCF7 (or MDA-MB-231) cells were grown in 25-cm2 flasks in
5 ml of medium (10% bovine calf serum and 10 mMHepes) at 37°C
in 5% CO2. Before infecting the MCF7 cells with the viral particles,
they were trypsinized and counted. Aliquots of 4 ml containing
70,000 to 80,000 cells per milliliter were placed in 15-ml tubes.
MCF7 cells were precipitated by centrifugation at 2000 rpm for5 minutes. The supernatant was removed and cells were gently
resuspended in 600 μl of viral particle suspension. The mixture was
divided in triplicates of 200 μl in 96-well plates and centrifuged at
2000 rpm for 90 minutes at 32°C. The plates were then placed at
37°C in 5% CO2 for 2 days to let the viruses infect the cells. The
triplicates of cells were then trypsinized and combined in cells of a 12-
well plate. After 2 days of incubation, the cells were transferred in the
same way to six-well plates and kept at 37°C in 5% CO2 for a
quarantine period of 4 weeks. The MCF7 medium was replaced twice
a week.
Flow Cytometry Experiments
About 250,000 MCF7 cells were seeded in 5 ml of MCF7 medium
in a six-well plate. Then, they were grown in 25-cm2 flasks in 5 ml of
medium (10% bovine calf serum and 10 mM Hepes) at 37°C in 5%
CO2. Each cell line (MCF7 control, empty vector, and MCMBP
knockdown) was seeded in triplicate. After 48 hours, cells were
trypsinized, pelleted (110g for 5 minutes), and resuspended in 800 μl
of staining solution (http://www.partec.com). The cells were filtered
through a 30-μm mesh and the nuclei were analyzed using the
CyFlow cytometer and FloMax software (http://www.partec.com).
Immunofluorescence Analysis of Breast Cancer Lines
MCF7 parental, empty vector control, andMCMBP knocked down
cells were grown in 25-cm2 flasks in 5 ml ofMCF7medium at 37°C in
5% CO2. Two days before the experiment, cells were trypsinized and
resuspended in 4.5 ml of fresh medium. Small coverslips were placed
inside 24-well plates and 1 ml of the cell suspension was added to every
coverslip. Cells were grown at 37°C in 5% CO2 for 2 days. Afterward,
cells were washed with 1 ml of PBS three times and fixed in
paraformaldehyde. Subsequently, 200 μl of 0.02% gelatin in PBS were
added to the coverslips and cells were incubated for 1 hour at room
temperature. A solution of 200 μl of gelatin in PBS buffer containing 1
μl of primary antibody anti-MCMBP, anti-MCM4 (ab4459), anti-
MCM6 (ab4458), anti-MCF7 (ab52489) (Abcam, Cambridge, UK),
or anti–E-cadherin was made. Gelatin was removed from the coverslips
and 200 μl of the primary antibody solution was added to the cells; they
were incubated for 1 hour at room temperature. Excess primary
antibodywas removed bywashing the cells three times with 1ml of PBS
buffer. A solution of 200 μl of gelatin in PBS buffer containing 0.5 μl of
secondary antibody, 2 mg/ml Alexa Fluor 488 goat anti-rabbit
antibody, or 2 mg/ml Alexa Fluor 594 goat anti-mouse antibody
(Invitrogen, Carlsbad, CA) was made, and 200 μl of the secondary
antibody solution was added to the cells; incubation was continued for 1
hour at room temperature in the dark. Excess secondary antibody was
removed by washing the cells three times with 1 ml of PBS buffer.
Coverslips were mounted on microscopic glass slides and counter-
stained with VECTASHIELD (Vector Laboratories, Burlingame, CA)
containing 4′,6-diamidino-2-phenylindole (DAPI). Cells were imaged
using the green channel of a BX61 Olympus epifluorescence
microscope equipped with a 1006/1.30 UPlan FLN objective coupled
to a U-C MAD 3 imaging system with the Cell-M imaging software
(Olympus, Tokyo, Japan). A minimum of 200 fields per construct was
scored, and multinucleated and/or micronucleated cells were counted.
Immunofluorescence Analysis of Colorectal Cancer Lines
DLD1 parental cells were grown in 25-cm2 flasks in 5 ml of RPMI
1640 medium supplemented with 10% fetal calf serum at 37°C in
5% CO2. The following small interfering RNA (siRNA) sequences
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for the specific transfections: human MCMBP (C10ORF119)
(SMARTpool; J-014474-09, J-014474-10, J-014474-11, and J-
014474-12) and control (SMARTpool non-targeting pool). The final
concentration of each siRNA was 30 nM. Immunofluorescence was
carried out as described above for the breast cell lines.
Quantitative PCR Analysis of MCMBP Expression and Cell
Cycle Analysis
Cells were collected with a rubber policeman 48 hours after
transfection. RNA was extracted with an RNeasy Animal Mini Kit
(Qiagen, Venlo, NL) and cDNAwas prepared with the cDNA Synthesis
System according to themanufacturer’s instructions (RocheDiagnostics).
For quantitative PCR (qPCR), a LightCycler 480 SYBR Green I Master
(RocheDiagnostics) was usedwith 100 nMprimers and 0.1mg of reverse
transcription reaction product. Reactions were run and analyzed on the
LightCycler 480 Real-Time PCR System according to manufacturer’s
instructions (Roche Diagnostics). All quantifications were normalized to
the expression levels of TATA box binding protein (TBP) and ubiquitin
C (UBC). Quantitative reactions were done in triplicate and averaged.
The primers were 5′ACTCTCCACGAAATACCACTTTG3′ and 5′
GTAGGATGTTGAGGGACTGACTCG3′ for MCMBP; 5′
TGAGCCAGTGCCAGAGCCAGA3′ and 5′GCTCCATCTTCTG-
CATCCACATC3′ for cyclin B1; 5′CCAAAGTTCCAGTTCAACC-
CACC3′ and 5′CAATCCACTAGGATGGCACGCA3′ for cyclin B2;
5′CCTTGCCAGAGCTTTTGGAATACC3′ and5′CACACTTCAT-
TATTGGGAGTGCCC3′ for Cyclin-dependent kinase 1 (CDK1); 5′
GTGGAGTGTTGGCTGTATCTTTGC3 ′ a n d 5 ′
GCTCCCGACTCCTCCATCTCAG3′ for Cyclin-dependent kinase
4 (CDK4); 5′TGCCGCTCTCCACCATCCG3′ and 5′
GGTTTCAGTGGGCACTCCAGG3′ for Cycline-dependent kinase
6 (CDK6); 5′CGGCTGTTTAACTTCGCTTC3′ and 5′CACACGC-
C A A G A A A C A G T G A 3 ′ f o r T B P ; a n d 5 ′
ATTTGGGTCGCGGTTCTTG3′ and 5′TGCCTTGACATTCTC-
GATGGT3′ for UBC.
HEK-293T Cell Culture and Transfection
For the overexpression of MCMBP, a lentiviral construct containing
the complete ORF of theMCMBP gene (C10ORF110) was purchased
from Open Biosystems (MHS1011-58896) and cloned in the
pDWPITetoMCMBPv5His vector. For the transfection experiments,
the previously prepared lentiviral vector was used at a final
concentration of 1 μg/μl. In an Eppendorf tube, 50 μl of CaCl2/
Hepes, 197 μl of Tris-EDTA (TE), and 3 μl of the lentiviral construct
containing MCMBP were mixed. This mix was added dropwise to 250
μl of Buffered Saline (BS)/Hepes in another Eppendorf tube. This final
mixture was gently vortexed for 1 minute and incubated at 37°C for 10
minutes. After incubation, the mix was added dropwise to 1.0 × 106
HEK cells in a T25 flask. After 6 hours, the medium was refreshed.
Chromosome Spreads and DAPI Staining
Forty-eight hours after transfection, subconfluent MDA-MB-231,
MCF10A, and HEK cells were treated with KaryoMAX Colcemid
(Invitrogen) to enrich for mitotic chromosomes. The complete
medium was replaced by 2 ml of medium at a final concentration of
KaryoMAX of 0.6 mg/ml. Cells were incubated at 37°C in 5% CO2
for 5 hours, harvested, trypsinized, pelleted (110g for 5 minutes), and
resuspended in 1 ml of a hypotonic solution of 60 mM KCl and left at
room temperature for 30 minutes. After incubation, the different cell
lines were pelleted twice (110g for 5 minutes) and resuspended infreshly made methanol/glacial acetic acid (3:1) added dropwise. Two or
three drops of suspended cells were applied to pre-cleaned smear glass
slides (Menzel-Glazer, Braunschweig, DE) and chromosomes were
counterstained with VECTASHIELD (Vector Laboratories) contain-
ing DAPI. Mitotic spreads of each cell population were imaged with
the DAPI channel of a BX61 Olympus epifluorescence microscope
equipped with a 1006/1.30 UPlan FLN objective coupled to a U-C
MAD 3 imaging system with the Cell-M imaging software (Olympus).
A minimum of 200 metaphases was evaluated per construct and
metaphases in which N70% of the chromosomes had separated sister
chromatids were scored as positives.
Immunohistochemistry for Tumor Samples
Tumor sections were deparaffinized and rehydrated as follows.
Sections were washed twice for 3 minutes in xylene and twice for 1
minute in, successively, isopropanol, 100% ethanol, and 70% ethanol.
They were finally rinsed with tap water and the antigens were retrieved
for 2 hours in 1× citrate buffer (Dako, Santa Clara, CA) using a Dako
retriever. The samples were then cooled down and rinsed with tap water.
Afterward, the tumor sections were immersed in a peroxidase-blocking
solution (1:9 solution of H2O2/methanol) for 10 minutes. After
incubation, the sections were washed three times for 5 minutes with
PBS. They were dried gently and the tumor sample was circled using a
Dako pen (Dako). Tumor samples were blocked for 45 minutes at room
temperature with a blocking buffer (Dako) enriched with 5% goat
serum. Afterward, the blocking buffer was removed by aspiration, the
primary antibody (1/100 dilution of MCMBP antibody in blocking
buffer) was added to the samples, and incubation was continued
overnight at 4°C. Afterward, tumor sections were washed three times for
5 minutes with PBS. As a secondary antibody, EnVision anti-rabbit
drop–HRP conjugated antibody was used; the section was covered with
a few drops and incubated for 45 minutes at room temperature. Slides
were developed by incubation with a liquid DAB solution for 30 seconds
to 1 minute until a positive reaction was observed. The reaction was
stopped by immersing the slides in bi-distillated water. The slides were
counterstained with hematoxylin (Mayer-Fluka) for 40 seconds. Finally,
the tumor samples were dehydrated by washing twice for 1 minute in,
successively, 70% ethanol, 100% ethanol, and isopropanol and twice for
3 minutes in xylene. Finally, slides were mounted with Depex. For each
tumor section, the normal tissue fraction and the tumoral fraction were
identified. At least 200 nuclei were selected in each fraction, and nuclei
that were stained were scored as positive for MCMBP expression.
Cox Survival Analyses
The microarray data analyzed in this study were downloaded
from the NCBI-Gene-Expression-Omnibus (GEO) website
(www.ncbi.nlm.nih.gov/geo). The Cel files of studies performed
on the HG133A or HG133plus2 Affymetrix array platforms with
samples from colorectal cancer (GSE17537), head and neck
carcinoma (GSE10300), leukemia (GSE23501), or lung carcino-
ma (GSE3141) were extracted, background-subtracted, normal-
ized, summarized (median polish option) using frozen robust
multiarray analysis (fRMA) [18], and converted back to signal
intensity values. Cox survival analysis was performed in R with
the Survival package using the raw expression intensity converted
in binary categories whether or not the expression value is above
a threshold value. This threshold was defined as the expression
value leading to the highest Chi-square value in a training Cox
survival analysis. To this end, the range of expression values for
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values before a Cox analysis was run for each interval value with
the data converted to 0 or 1, according to whether the MCMBP
expression value is below or above the considered interval value.Immunofluorescence Analysis of Histone H2A.X
MCF7 parental, empty vector control, and MCMBP knocked
down cells were grown in 25-cm2 flasks in 5 ml of MCF7 medium
at 37°C in 5% CO2. Two days before the experiment, cells were
trypsinized and resuspended in 4.5 ml of fresh medium. Small
coverslips were placed inside 24-well plates and 1 ml of the cell
suspension was added to each coverslip. Cells were grown at 37°C
in 5% CO2 for 2 days. Afterward, the cells were washed three times
with 1 ml of PBS and fixed with 500 μl of methanol. The cells were
then frozen at −20°C for 10 minutes. Methanol was removed from
the coverslips and the cells were washed three times with 1 ml of
PBS buffer. Subsequently, 200 μl of 0.02% gelatin in PBS solution
were added to the coverslips and the cells were incubated for 1 hour
at room temperature. A solution of 200 μl of gelatin in PBS buffer
and 1 μl of primary antibody (0.05 μg/ml anti–phospho-histone
H2A.X–ser-139 antibody, Catalog No. 05-636; Millipore, Biller-
ica, MA) was made. Gelatin was removed from the coverslips and
200 μl of primary antibody solution was added to the cells and
incubation was continued for 1 hour at room temperature. Excess
primary antibody was removed by washing the cells three times
with 1 ml of PBS buffer. A solution of 200 μl of gelatin in PBS
buffer and 0.5 μl of secondary antibody (2 mg/ml Alexa Fluor 488
goat anti-mouse antibody, Invitrogen) was made and 200 μl of this
secondary antibody solution was added to the cells. Incubation was
continued for 1 hour at room temperature in the dark. Excess
secondary antibody was removed by washing the cells three times
with 1 ml of PBS buffer. Coverslips were mounted on microscope
glass slides and counterstained with VECTASHIELD (Vector
Laboratories) containing DAPI. Cells were imaged using the green
channel of a BX61 Olympus epifluorescence microscope equipped
with a 1006/1.30 UPlan FLN objective coupled to a U-C MAD 3
imaging system with the Cell-M imaging software (Olympus). A
minimum of 100 nuclei per construct were selected and the histone
H2A.X foci were counted in each nucleus.qPCR Analysis of Tumor Samples
Tumor RNA was extracted with an RNeasy Animal Mini Kit
(Qiagen) and cDNA was prepared with the cDNA Synthesis System
according to the manufacturer’s instructions (Roche Diagnostics). For
qPCR, a LightCycler 480 SYBR Green I Master (Roche Diagnostics)
was used with 100 nM primers and 0.1 mg of reverse transcription
reaction product. Reactions were run and analyzed on the LightCycler
480 Real-Time PCR System according to the manufacturer’s
instructions (Roche Diagnostics). All quantifications were normalized
to the expression levels of TBP and UBC. Quantitative reactions were
done in triplicate and averaged. The primers were 5′ACTCTCCAC-
GAAATACCACTTTG3′ and 5′GTAGGATGTTGAGGGACT-
GACTCG3′ for MCMBP; 5′CGGCTGTTTAACTTCGCTTC3′
and 5′CACACGCCAAGAAACAGTGA3′ for TBP; and 5′
ATTTGGGTCGCGGTTCTTG3 ′ and 5 ′TGCCTTGA
CATTCTCGATGGT3′ for UBC.Results
Coexpression and GO Analyses Confirm that MCMBP Is
Involved in Cohesion Processes
Our previous studies demonstrated that ETG1-deficient plants
(plant orthologue of MCMBP) undergo endogenous DNA stress and
display a transient cell cycle arrest. A microarray transcriptomic
analysis of wild-type and ETG1-deficient Arabidopsis plants revealed
in the knockout plants a significant enrichment of genes involved in
the cell cycle, mitotic cell cycle, microtubule-based movement, and
sister chromatid cohesion [14]. To explore whether these functional
processes were also associated with MCMBP, the human orthologue
of ETG1, we tested whether the coexpression neighborhood of
MCMBP was functionally enriched in GO categories related to M-
phase progression (see Materials and Methods section). Indeed, the
MCMBP coexpression neighborhood was found to be significantly
enriched in processes related to M-phase progression, chromosome
segregation, and sister chromatid cohesion (P value b .01 according to
a multiple t test, with false discovery rate corrected; Figure 1).
Similarly, among the top 50 MCMBP coexpressed genes, it was
possible to identify coexpression neighbors that were directly involved
in cohesion processes (Table 1).
MCMBP Depletion Causes Aberrant Cohesion Events in
Different Cell Types
A role for MCMBP in sister chromatid cohesion was identified
previously in HEK-293T cells. Depletion of MCMBP strongly
affected sister chromatid cohesion, resulting in a higher proportion
of nuclei with completely separated sister chromatids in compar-
ison with controls [14]. To determine whether the effect on sister
chromatid cohesion seen upon MCMBP knockdown in HEK cells
is also present in other cell lines, MCMBP transcripts were
knocked down in different breast cell lines. For the non-
transformed epithelial cell line MCF10A, transient knockdown
was achieved by using pooled short interference RNAs, whereas for
the MDA-MB-231 breast cancer cell line, cellular cultures with a
stable MCMBP knockdown were produced using lentiviral
transduction (see Material and Methods section). MCMBP
knockdown affected sister chromatid cohesion in both cell lines,
suggesting that the effect is a specific phenotype caused by
MCMBP depletion (Figure 2).MCMBP Misexpression Triggers Formation of Polylobed
Nuclei and Micronuclei in Breast and Colorectal Cell Lines
We showed that highMCMBP gene expression levels are associated
with a diminished probability of survival of breast carcinoma patients
[19]. To identify the role of MCMBP in carcinogenesis, the effects of
knocking down or overexpressingMCMBP were studied in the MCF7
breast cancer cell line. To that end, cell lines either constitutively
overexpressing or silencing the MCMBP gene were generated. For
studies at the protein level, a high-quality antibody against theMCMBP
protein was generated (Supporting Information Figure S1).
MCMBP knocked down cultures were studied at the cellular level
by flow cytometry, revealing a shoulder on the ploidy profile formed
by a subpopulation of cells with a DNA content higher than 4C
(Figure 3A). This cell population was correlated with the appearance
of multinucleated (polylobed) and/or giant cells compared to the
untransduced or control transduced cells. The number of multinu-
cleated cells was almost five-fold higher in the knocked down cultures
Figure 1. BiNGO (GO enrichment) analysis of the top 300 genes coexpressed with MCMBP. The yellow-to-orange color of the circles
corresponds to the level of significance of the overrepresented GO category (P value b .01 according to a multiple t test with correction of
false discovery rate). The size of the circle is proportional to the number of genes in the category. A clear overrepresentation of GO terms
associated with M-phase processes and sister chromatid cohesion can be observed.
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the MCMBP protein (Figure 3B). In MCF7 control cells, MCMBP
was weakly present in a small proportion of multinucleated cells
(Figure 3B). These cells might have arisen specifically because of
MCMBP deregulation, given the presence of proteins belonging to
the MCM complex in control multinucleated MCF7 cells
(Supporting Information Figure S2). This phenotype was accompa-
nied by the transcriptional up-regulation of specific cell cycle
markers, such as cyclin B1, cyclin B2, and CDK1 (Figure 3D). Like
the knockdown lines, MCMBP-overexpressing MCF7 cultures
displayed multinucleated cells but accompanied by micronuclei
(Figure 3E). The number of multinucleated cells was four-fold higherTable 1. List of Genes Significantly Associated with the GO Term “Sister Chromatid Cohesion”
(P value b .01) that Are Present in the MCMBP Coexpression Neighborhood (Top 50).
Official Symbol Functional Annotation
CTCF CCCTC-binding factor (zinc finger protein)
MAD2 MAD2 mitotic arrest deficient-like 1 (yeast)
SEH1L SEH1-like (Saccharomyces cerevisiae)
SRPK1 SFRS protein kinase 1
BUB3 Budding uninhibited by benzimidazoles 3 homolog (yeast)
CDC23 Cell division cycle 23 homolog (S. cerevisiae)
NUP37 Nucleoporin 37 kDa
STAG1 Stromal antigen 1
SMC1A Structural maintenance of chromosomes 1A
SMC2 Structural maintenance of chromosomes 2
SMC3 Structural maintenance of chromosomes 3
SMC4 Structural maintenance of chromosomes 4relative to controls (Figure 3F). Here, cell cycle marker genes were
transcriptionally upregulated (Figure 3G).
It has been proven that the appearance of multinucleated cells and/or
cells with micronuclei is directly linked with different forms of CIN,
including cohesion defects [20]. Given the observations thatMCMBP
links DNA replication with sister chromatid cohesion [13,14], the
aberrant nuclei observed in theMCMBP misexpression cultures might
have originated due to defects in sister chromatid cohesion. As the
overexpression ofMCMBP also has a direct effect on the generation of
multinucleated cells and/or cells harboring micronuclear structures, we
tested the effects of transient MCMBP overexpression in HEK-293T
cells on chromosomal structure. Again, effects on sister chromatid
cohesion were observed. When the cells overexpressingMCMBP were
examined in detail at metaphase, close to 70% of the metaphases were
found to be disrupted, illustrating that in human cells not only
depletion but also overexpression ofMCMBP has a direct effect on sister
chromatid cohesion (Figure 4).
As mentioned before, colorectal carcinomas have high rates of
genetic instability. Multinucleation and micronucleation represent
common cellular aneuploidization processes derived from genetic
instability events [21,22]. Due to this, we decided to evaluate whether
the phenotypes related to genetic instability seen in breast cancer lines
are reproducible in the DLD1 colorectal cancer line.
The MCMBP transcript was transiently depleted by siRNA in
the DLD1 cell line. As observed in the MCF7 cell lines,
multinucleated and/or giant cells staining negative for the
MCMBP protein were also observed in the colorectal cell
line (Figure 5A). The number of multinucleated cells was almost
Figure 2. Knockdown of the MCMBP transcript has a direct effect
on sister chromatid cohesion in different breast cancer cell lines.
(A) Examples of metaphases wherein the sister chromatids are
separated when the MCMBP transcript is deregulated, either
transiently (MCF10A cell line) or in a stable manner (MDA-MB-231
cell line). Insets show higher magnification images of single sister
chromatid pairs. For the MDA-MB-231 cells, control refers to the
empty vector used for the lentiviral transfection, while for MCF10A
cells, control refers to a pool of siRNAs designed not to target any
gene in the human genome. (B) Quantification of disrupted
metaphases for the analyzed cell lines. Disrupted metaphases
refer to metaphases in which at least 70% of the chromosomes
have totally separated sister chromatids. (C) qPCR analysis of the
cultures showing depletion of the MCMBP transcript in the breast
cancer cell lines.
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controls (Figure 5B).
Knockdown of MCMBP Triggers the Response of DNA
Stress Genes
Aneuploidization events are accompanied by the induction of the
DNA stress response machinery. To test whether MCMBP
depletion could trigger specific DNA stress response events,
immunolocalization of the phosphorylated H2A.X histone using a
specific antibody was carried out in MCF7 cultures. Phosphoryla-
tion of histone H2A.X was rarely observed in parental MCF7 cells or
in cells transformed with the empty vector. In contrast, histone
H2A.X phosphorylation was enhanced in the MCMBP knocked
down cells (Figure 6). These results suggest that the absence of a
functional MCMBP protein triggers the DNA stress response in
MCF7 cells. These data are in agreement with recent data
illustrating that depletion of MCMBP triggers the replication stress
response in HeLa cells [23].
MCMBP Misexpression Correlates with Changes in Relapse
Risk Probability of Different Carcinomas
Previously, we had shown the correlation that exists in breast
carcinomas between MCMBP misexpression and relapse-free survival
probability [19]. Concomitantly, experiments performed in breast
tumor tissue revealed that MCMBP overexpression is directly linked
with the estrogen receptor (ER) negative status, a hallmark of poor
prognosis and difficult treatment of breast cancers (Supporting
Information Figure S3), confirming the value of MCMBP as a
prognostic marker.
To address the use of MCMBP transcript levels as a prognostic
marker for cancer progression in different carcinomas, we extended
our previously reported Cox analyses [19] to different types of
cancers to detect whether in these neoplasias a change in MCMBP
gene expression is associated with changes in relapse risk probability.
To perform these analyses, our database of transcriptional profiles
linked to well-annotated clinical information, including relapse
events and relapse time, was extended to include different microarray
expression experiments representing different human carcinoma
types (see Materials and Methods section). The significance of a
particular association between MCMBP gene expression and a
relapse event was assessed by Cox regression analysis. Figure 7 shows
that for different carcinomas both increased and reduced MCMBP
gene expression are directly associated with an increment in relapse
risk probability.MCMBP Is ExpressedMore Strongly inMalignantly Transformed
Cells than in Normal Proliferating Tissue
To study further the role of MCMBP in carcinogenesis, different
tumor samples were studied at the protein level by immunohisto-
chemistry. To determine whether MCMBP protein accumulation
is associated with proliferation, normal tissues and tumor sections
were analyzed and compared with samples stained with the Ki-67
antibody. The immunostainings revealed a strong correlation
between MCMBP and Ki-67 accumulation: Ki-67–positive
samples stained strongly positive for MCMBP, and samples
negative for MCMBP were negative for Ki-67 (Figure 8).
Interestingly, in breast cancer xenografts, Ki-67 identified
proliferating cells in the tumor and also in the surrounding skin,
whereas the MCMBP antibody identified proliferating cells in
Figure 3. Cellular analysis of MCF7 cells in which MCMBP is knocked down or overexpressed. (A) Flow cytometry profiles of cells with
MCMBP knockdown in comparison with controls. Upon knockdown, a subpopulation of cells with DNA content higher than 4C appeared
in the culture. (B) A correlation exists between multinucleation and reduction or absence of MCMBP protein expression in those types of
cells, both in control and knocked down cultures. (C) Quantification of the multinucleated cells present in the different cultures. (D) Up-
regulation of specific cell cycle markers on MCMBP knockdown. (E) On MCMBP overexpression, multinucleated cells and micronuclei
(arrows) can be observed. (F) Quantification of the multinucleated cells present in the different cultures. (G) Up-regulation of specific cell
cycle markers on MCMBP overexpression.
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skin, suggesting that MCMBP staining predominantly marks cells
that are malignantly proliferating (Figure 9).To confirm a direct link between MCMBP levels and cancer
progression and to validate the potential use of the MCMBP antibody
in cancer diagnosis and/or prognosis, the immunohistochemical
Figure 4. Overexpression of MCMBP has a direct effect on sister
chromatid cohesion in HEK-293T cells. (A) Examples of meta-
phases in which the sister chromatids become separated when the
MCMBP transcript is upregulated. Insets show higher magnification
images of single sister chromatid pairs. (B) Quantitation of the
phenotype: almost 70% of the metaphases are disrupted when
MCMBP is overexpressed. (C) qPCR showing that the MCMBP
transcript is upregulated almost 200-fold in theMCMBP-overexpressing
cell line.
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carcinomas because according to our data, MCMBP has a
fundamental role in genetic instability originated mainly from
cohesion defects. Compelling evidence suggests that cohesion is a
key deregulated process, particularly in colorectal cancers [7,8].
Twenty human colon adenocarcinoma samples were analyzed in
detail. We selected tumor samples containing normal colon
epithelium tissue in order to make direct comparisons betweenFigure 5. Cellular analysis of MCMBP-depleted DLD1 cell line. (A)
absence of MCMBP protein expression inMCMBP knocked down cu
analyzed cultures of the DLD1 cell line. (C) qPCR analysis showing dtumoral and normal tissues. In addition, this cohort contained tumors
with different degrees of progression, ranging from well-differentiated
colon adenocarcinomas to poorly differentiated carcinomas. Patho-
logic analysis of the samples revealed that normal epithelium had
weak to moderate staining of MCMBP at the base of the crypts, the
region where proliferative regeneration occurs. In contrast, MCMBP
positivity disappeared toward the surface of the crypt at the site of the
lumen, where cell division is not active and cells are differentiated
(Figure 10B). Interestingly, in some other structures, MCMBP
protein abundance was associated with proliferating cells in normal
tissue. This was the case of the lymph nodules in peripheral lymph
tissue in which the germinal centers, which contain B-cells that
proliferate and mutate by somatic hypermutation, were moderately
stained with the MCMBP antibody (Figure 10C). The same was
observed in mucinous adenocarcinoma, where staining for MCMBP
in the mucinous cancer cells, which are more differentiated, was
weaker than in less differentiated cancer cells (Figure 10D).
Strikingly, in most of the tumors, there was more abundant
accumulation of MCMBP in comparison with the normal mucosa.
In a few tumor samples, the staining for MCMBP was weak but still
stronger than in normal tissue. In the tumoral fractions of the
different types of carcinomas, MCMBP was remarkably abundant in
the nuclei; the positivity was also detected to a lesser extent in the
cytoplasm (Figure 10, E–H and Table 2). Finally, at the invasion
front of the tumors, there was no clear difference in MCMBP
abundance in comparison with the rest of the tumor mass.
Given the positive direct association between MCMBP accumulation
and the presence of malignantly proliferating cells, we decided to include
more tumors in our histologic analyses. So, we selected 54 tumors (with
the same characteristics and conditions used for the previously studied
cohort) for which detailed clinical information was available (Table 3).
The pathologic analysis of this new cohort of tumors confirmed the
observations obtained with the previous one: the majority of the
tumors had a clearly greater accumulation ofMCMBP in comparison
with the normal mucosa and the normally proliferating tissue.
Additionally, in this new set of tumors, we found a significantThere is a correlation between multinucleation and reduction or
ltures. (B) Quantification of the multinucleated cells in the different
epletion of the MCMBP transcript in the studied DLD1 cell lines.
Figure 6. Immunostainings of phosphorylated histone H2A.X in MCF7 cells. (A) On MCMBP knockdown, the DNA stress response
checkpoint is activated, as illustrated by the enhanced phosphorylation of the histone H2A.X. (B) qPCR analysis of the different MCF7 lines
used in the experiment; 80% of theMCMBP transcript is reduced in the stable knocked down MCF7 line. (C) Quantitation of the histone
H2A.X foci observed in the control nuclei in comparison with the MCMBP knocked down cells.
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MCMBP accumulation. Most of the poorly differentiated adeno-
carcinomas retained MCMBP accumulation in N90% of the tumor
mass, representing a statistically significant association (P b .05
according to the hypergeometric distribution).
Discussion
Colorectal cancer accounts for about one million new cases every year,
and it is the second most frequently diagnosed internal malignancy
worldwide [24]. These statistics stress out the necessity of looking for
new strategies for better diagnosis and treatment of this disease.
Colorectal carcinomas display heterogeneous distinctive character-
istics, and their origin is due to a compendium of diverse natural
histories, pathologic features, and aberrations in distinct molecular
pathways that converge to cause the malignancy [25,26]. It has been
proposed that three major drivers are involved in the generation of
colorectal carcinomas: CIN, the CpG island methylator phenotype,
and microsatellite instability. The predominant abnormality is CIN,
accounting for up to 85% of cases [27]. Nevertheless, only few genes
that might contribute to CIN governing colorectal cancers have been
identified. It was shown that genes involved in sister chromatid
cohesion are frequently mutated in colorectal carcinomas and their
disruption leads to CIN in this type of neoplasias [7].
Here, we demonstrated that MCMBP knockdown in MCF7 cells
induces the accumulation of a subpopulation of cells that are
multinucleated with polylobed nuclei. When we studied the
depletion of the MCMBP protein by using a specific antibody
against MCMBP, we observed that the multinucleated cells in the
MCMBP knocked down cultures were MCMBP negative. These
observations were corroborated in different colorectal cell lines.Strikingly, also by overexpressing the MCMBP transcript in MCF7
cell cultures, we observed an increase in the number of multinucleated
cells, together with the appearance of micronuclei. These observations
confirm recent studies that identified a direct link between MCMBP
expression and nuclear morphology [23].
It has been shown that a correlation exists between sister
chromatid cohesion phenotypes, chromosome-segregation defects,
and the appearance of multinucleated polylobed cells. Nguyen and
collaborators showed that when the Aurora-B protein is misregu-
lated, there is accumulation of multinucleated cells, which can
promote tumorigenesis [28]. Similarly, in a genome-wide screening
for genes related to cell division, Neumann and colleagues showed
that genes that are necessary for the proper separation of the
chromosomes could be clustered according to specific phenotypes
that have in common the production of multinucleated cells [29].
Chromosomal missegregation and its direct consequence, the
production of aneuploid cells, is a new hallmark of neoplastic
transformation [3]. Aneuploid cells are prompted to become cancer
cells due to the generation of an imbalanced genome, which amplifies
oncogenes in some cells and restrains tumor suppressors in others
[25]. The MCMBP protein might participate in oncogenic
transformation by the generation of aneuploid multinucleated cells
due to its effects on chromatid cohesion. Therefore, its deregulation
might be regarded as a driver mutation in the oncogenic process. This
is emphasized by the observation that even in MCF7 control cells
MCMBP is scarce in a small proportion of spontaneously occurring
multinucleated cells. These cells might arise specifically because of
MCMBP deregulation, given that control multinucleated MCF7
cells express other proteins belonging to the MCM complex
(Supporting Information Figure S2).
Figure 7. Examples of Cox survival plots for specific carcinomas. For colon and head and neck carcinomas and for leukemia, a clear
association between increased MCMBP gene expression level and diminished probability of survival is illustrated. Contrary to lung
carcinoma, in which when MCMBP is weakly expressed, the relapse-free survival probability is reduced (RRC, relative risk coefficient;
asterisk represents statistically significant differences in the survival probability with P b .05, and n is the number of patients taken into
account for the construction of the survival plots).
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coupled to the replication process and occurs very near the replisome.
Cohesion is initiated by the acetyltransferase ECO1/CTF7, which
travels along the DNA together with replication forks [30].
Furthermore, in yeast the depletion or mutation of several
nonessential components of the replisome, such as the replication
factor CTF18, causes cohesion defects [31,32]. By associating with
MCM proteins, MCMBP is very likely a component of the replisome
[33], and according to the results presented here, it also plays a role in
establishing cohesion during the replication process. MCMBP has
been described as a new member of the MCM complex [14], and at
the same time, it is strongly coexpressed with genes related to sister
chromatid cohesion, such as MAD2 mitotic arrest deficient-like 1
(MAD2), budding uninhibited by benzimidazoles 3 homolog
(BUB3), and the members of the structural maintenance of
chromosomes (SMC) complex (Table 1).
Spindle checkpoint regulators, such as the BUB kinases and
MAD2, protect cells from aberrant chromosome segregation and
might therefore function as suppressors of malignant transformation.
Interestingly, MAD2 is either upregulated or downregulated
depending on the tumor type, and in both cases, these alterations
result in chromosomal imbalances and tumor development [34,35].
Some other genes related to cohesion and chromosome segregation
processes behave like MAD2, being overexpressed in certain types of
carcinomas and downregulated in others and, in both cases, resultingin abnormal chromosome structure. For example, this is true for the
Aurora kinases [36,37] and the Polo-like kinase 1 [38,39].
Interestingly, down-regulation or overexpression of MCMBP in
HEK-293T cells produced similar effects on the cohesion of sister
chromatids, suggesting that regulation of molecules involved in this
process must be tightly controlled in order to avoid problems in DNA
replication and DNA repair that can result in carcinogenic events.
Supporting this, recent evidence from human cell cultures suggests
that MCMBP overexpression can lead to nuclear abnormalities
similar to those associated withMCMBP depletion, indicating that an
excess of MCMBP can be as detrimental as lack of it [23]. Thus,
precise levels of MCMBP might be required to avoid CIN events.
However, no Arabidopsis thaliana overexpressing ETG1 could be
obtained (unpublished data), suggesting that high ETG1 levels
interfere with the plant generation process and signifying that
overexpression of ETG1 and MCMBP is probably more deleterious
than its depletion. Correspondingly, a larger number of disrupted
metaphases in HEK cells were observed on MCMBP overexpression
than on transcript depletion. Alternatively, as demonstrated recently,
MCMBP overproduction could exert its phenotypic effects by
creating a domain-negative version of the molecule [12].
Misregulation of the role ofMCMBP in cohesion might not be the
only factor that accounts for cancer progression. As mentioned above,
defects either in the replication process or in checkpoint responses
increase the susceptibility to cancer by triggering genome instability
Figure 8. Immunohistochemical analysis of different tumor sections showing a high correlation between Ki-67 and MCMBP
accumulation. Mouse tumors highly positive for Ki-67 are also positive for MCMBP and vice versa.
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function links the replication process with sister chromatid cohesion.
Therefore, it might act synergistically with both the origin and the
progression of specific carcinomas.Figure 9. Breast cancer xenografts stained for Ki-67 andMCMBP. Ki-6
Contrastingly, MCMBP identifies proliferating cells from the tumor, bu
that MCMBP preferentially detects malignant cells.It is known that an excessive amount of MCM2–7 complex is
loaded onto the origins of replication before the replication process
starts [41]. Although a huge number of potential replication origins
exist throughout the genome, activation of only a fraction of them is7 identifies proliferating cells from the tumor and also from the skin.
t its staining is weak in proliferating cells of normal skin, suggesting
Figure 10. MCMBP protein levels in normal replicating cells and tumoral tissue. (A) In general, normal epithelium showed weak to
moderate staining of MCMBP. (B) MCMBP protein is well expressed (arrow) at the base of the normal crypts (near the muscularis
mucosae, light blue bar on top of the picture), corresponding to the proliferative stem and transient amplifying cell compartments from
where regeneration happens. Contrastingly, MCMBP positivity disappears toward the surface of the crypt at the site of the lumen, where
cell division is not active and cells are strongly differentiated (dark blue bar on top of the picture). (C) In lymphoid follicles, the germinal
centers (arrow), which are sites that contain actively replicating B-cells, MCMBP is detected. (D) In the mucinous adenocarcinoma type,
the mucinous cancer cells, which are more differentiated and responsible for the abnormal mucus production (red arrows), stained
weaker for MCMBP in comparison with the highly MCMBP-positive cancer cells (light blue bar on top of the picture). There was a stronger
expression of MCMBP in most tumors than in normal mucosa. MCMBP is abundant in the nuclei of tumor cells. (E) Well-differentiated
adenocarcinoma. (F) Moderately differentiated adenocarcinoma. (G) Poorly differentiated adenocarcinoma. (H) Quantification of MCMBP-
positive cells in the tumor mass of the carcinomas in comparison with the normal tissue.
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replicative stress resulting from external sources or coming from the
DNA replication process itself, many replication forks are stalled. For
the replication process to continue, dormant origins licensed by excess
MCM2–7 complexes are used as backups for these emergency
situations, increasing the number of replication forks and promoting
the completion of DNA replication [43]. Reduced levels of MCM2–7
proteins in mice causes spontaneous tumors with complete
penetrance [44], suggesting that dormant origins play an important
role in such conditions. These mouse models exhibited an abundance
of spontaneous micronuclei, which is a characteristic of chromosome
instability. Similarly, the MCM4 chaos3 allele, encoding a point
mutation in the MCM4 gene that compromises the stability of the
MCM complex, leads to a reduced number of dormant origins. This
reduction of dormant origins results in accumulation of stalled
replication forks. Despite the activation of multiple DNA repair
pathways, a significant fraction of stalled replication forks persist into
the M phase, interfering with chromosome segregation [43,45].Interestingly, in our study, the knockdown of theMCMBP transcript
also triggered the response of DNA stress genes.
It was shown that MCMBP regulates the unloading of the MCM
complex during the late S phase. In Xenopus egg extracts, MCMBP
can destabilize and disassemble the MCM2–7 complex and might
function as an unloader of the MCMs from chromatin [11]. This
phenotype is also seen in Schizosaccharomyces pombe [12]. Given that
MCMBP is important for destabilization and disassembly of the
MCM complex, the overexpression of MCMBP could lead to
premature destabilization of the complex. This has a direct effect on
the rescue of the stalled replication forks and compromises DNA
replication and chromosome stability (Figure 11). The additive effect
of a defect in the mechanism that rescues stalled replication forks,
combined with the emerging cohesion defects caused by MCMBP
overexpression, might have a strong effect on chromosomal stability.
Due to this, it was expected that MCMBP would be strongly
overexpressed in the colorectal adenocarcinoma tumors, which are the
archetypical examples of carcinomas derived from CIN processes.
Table 2. Detailed Pathologic Analysis of the Colorectal Adenocarcinoma Samples.
Tumor Information MCMBP Staining






Cells in the Tumor
1586472 MD after RCT Strong Strong N90
1588283 WD to MD Strong Strong N90
1586788 MD after RCT Moderate Light 70
1587630 MD Strong Strong N90
1587605 WD to MD Strong Strong 70
1588382 MD Strong Strong N90
1588619 MD to PD Strong Strong 70
1588677 MD Moderate Light N90
1586813 MD Moderate Strong 80
1588204 WD Strong Strong N90
1589162 PD Light Moderate 80
1588915 MD Strong Strong N90
1321831 MD Moderate Light 60
1324028 MD Strong Light 70
1324038 MD Moderate Moderate N90
1324941 MD Strong Strong N90
1328264 MD + PD Strong Strong N90
1325706 PD (mucinous type) Strong Strong N90
1335290 MD Strong Moderate N90
1321369 MD Moderate Light 50
WD, MD, and PD, well-, moderately, and poorly differentiated adenocarcinomas, respectively.
RCT, radio-chemotherapy.
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but in certain instances it also accumulated in the cytoplasm (Table 2). It
has been documented that overexpression of theMCMBP orthologue in
yeast results in delocalization and migration of the MCM subunits to the
cytoplasm, causing abnormal replication [12]. Cytoplasmic presence of
MCMBP might represent the premature destabilization of the whole
MCM complex by its asynchronous action, another evidence of the role
of MCMBP in carcinogenesis.
Evidence is accumulating for a tight relationship between members
of the MCM complex and cancer. MCM2 was found to be a strong
prognostic marker of breast cancer [46] and is also used to detect
colorectal cancers [47]. Similarly, MCM proteins were considered as
pre-cancer markers of esophageal cancers [48], and MCM2 and
MCM4 were found to be independent predictors of survival in
patients with non–small cell lung cancer [49].
Here, we have given consistent evidence illustrating that the novel
replisome factor MCMBP can be considered a useful marker for cancer
research. According to our Cox survival analyses, altered expression of
MCMBP has a significant prognostic value in different types of cancers.
Furthermore, its overexpression in breast carcinomas is directly linked
with the estrogen receptor (ER) negative status, a hallmark of poor
prognosis and difficult treatment of breast cancers (Supporting
Information Figure S3). Altogether, our data suggest that deregulated
MCMBP expression might be a cause of carcinogenesis in a wide
spectrum ofmalignancies.MCMBP, its demonstrated prognostic value,
and knowledge of its mechanism of action pave the way for its use in
cancer diagnosis and maybe treatment.
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